Patents by Inventor Henryk T. Dudek

Henryk T. Dudek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAI CONJUGATES AND USES THEREOF
    Publication number: 20240124875
    Abstract: The subject matter disclosed herein is directed to modulating gene expression using siRNA compositions and methods directed to affecting key cell populations supporting the growth and metastasis of cancer to affect the beneficial treatment, remission or removal of the underlying tumor in a patient.
    Type: Application
    Filed: March 4, 2022
    Publication date: April 18, 2024
    Inventors: Shanthi GANESH, Marc ABRAMS, Henryk T. DUDEK, Harini Sivagurunatha KRISHNAN
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11912996
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: February 27, 2024
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 11873493
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: January 16, 2024
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • COMPOSITIONS AND METHODS FOR INHIBITING MAPT EXPRESSION
    Publication number: 20230416742
    Abstract: Oligonucleotides are provided herein that inhibit MAPT gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., lipid moiety). Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders, and/or conditions associated with MAPT gene expression.
    Type: Application
    Filed: May 12, 2023
    Publication date: December 28, 2023
    Inventors: Bob Dale BROWN, Henryk T. DUDEK, Seongmoon CHEONG, Shiyu WANG, Travis GRIM, Matthew Guese COSTALES, Maire JUNG
  • COMPOSITIONS AND METHODS FOR INHIBITING SNCA EXPRESSION
    Publication number: 20230416743
    Abstract: Oligonucleotides (e.g., RNAi oligonucleotides) are provided herein that inhibit SNCA gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., GalNAC moiety or lipid moiety). Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders, and/or conditions associated with SNCA gene expression.
    Type: Application
    Filed: May 12, 2023
    Publication date: December 28, 2023
    Inventors: Bob Dale BROWN, Henryk T. DUDEK, Seongmoon CHEONG, Shiyu WANG, Travis GRIM, Matthew Guese COSTALES, Maire JUNG
  • CHEMICAL MODIFICATIONS FOR INHIBITING EXPRESSION OF ALDH2
    Publication number: 20230416752
    Abstract: This disclosure relates to chemically modified oligonucleotides, compositions, and methods useful for reducing ALDH2 expression, to treat alcoholism. Disclosed oligonucleotide for the reduction of ALDH2 expression is modified for enhanced pharmacological properties.
    Type: Application
    Filed: November 12, 2021
    Publication date: December 28, 2023
    Inventors: Bob Dale BROWN, Henryk T. DUDEK, Utsav SAXENA
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 11851658
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: December 26, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • COMPOSITIONS AND METHODS FOR MODULATING SCAP ACTIVITY
    Publication number: 20230374522
    Abstract: Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders, and/or conditions associated with SCAP activity such as nonalcoholic fatty liver disease (NAFLD), (NASH), dyslipidemia, atherosclerotic cardiovascular disease (ASCVD), and/or other SCAP-associated conditions, diseases, and/or disorders.
    Type: Application
    Filed: April 14, 2023
    Publication date: November 23, 2023
    Inventors: Bob Dale BROWN, Henryk T. DUDEK, Seongmoon CHEONG, Nicole Alexis SPIEGELMAN
  • COMPOSITIONS AND METHODS FOR INHIBITING GYS2 EXPRESSION
    Publication number: 20230365974
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Application
    Filed: January 18, 2023
    Publication date: November 16, 2023
    Inventors: Bob D. Brown, Natalie PURSELL, Henryk T. DUDEK, Cheng LAI
  • Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
    Patent number: 11773390
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: October 3, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 EXPRESSION
    Publication number: 20230287425
    Abstract: Oligonucleotides are provided herein that inhibit angiopoietin-like protein 3 (ANGPTL3) expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with ANGPTL3 expression.
    Type: Application
    Filed: March 18, 2021
    Publication date: September 14, 2023
    Inventors: Bob D. BROWN, Henryk T. DUDEK, Utsav SAXENA, Marc ABRAMS, Anton TURANOV
  • PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS
    Publication number: 20230250435
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of PCSK9 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of PCSK9 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hypercholesterolemia, atherosclerosis, and/or one or more symptoms or complications thereof.
    Type: Application
    Filed: November 30, 2022
    Publication date: August 10, 2023
    Inventors: Henryk T. DUDEK, Jihye Park
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
    Patent number: 11697812
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: July 11, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA
    Patent number: 11667918
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: June 6, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for inhibiting expression of LDHA
    Patent number: 11661604
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: May 30, 2023
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20230069235
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 2, 2023
    Inventors: Bob D. BROWN, Henryk T. Dudek
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA
    Publication number: 20230058834
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: July 1, 2021
    Publication date: February 23, 2023
    Inventors: Bob D. BROWN, Henryk T. DUDEK
  • Compositions and methods for inhibiting GYS2 expression
    Patent number: 11572562
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: February 7, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
  • PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
    Patent number: 11566248
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of PCSK9 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of PCSK9 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hypercholesterolemia, atherosclerosis, and/or one or more symptoms or complications thereof.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: January 31, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Henryk T. Dudek, Jihye Park
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA
    Publication number: 20220396793
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: June 9, 2022
    Publication date: December 15, 2022
    Inventors: Bob Dale BROWN, Henryk T. DUDEK